Mechanisms of bone lesions in multiple myeloma and lymphoma

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1557-1563

  Roodman, G David ^a  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

1,25 (OH)2D3; Bone lesions; Interleukin 1; Lymphoma; Myeloma; Parathyroid hormone related protein

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; PARATHYROID HORMONE RELATED PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

BONE DESTRUCTION; BONE METASTASIS; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; HUMAN CELL; HYPERCALCEMIA; LYMPHOMA; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0030791806     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1557::aid-cncr5>3.0.co;2-h     Document Type: Conference Paper

References (39)

1. Roodman GD. Osteoclast function in Paget's disease and multiple myeloma [review]. Bone 1995;17:57S-61S.
2. Peter SA, Cervantes JF. Hypercalcemia associated with adult T-cell leukemia/lymphoma (ATL) [review]. J Natl Med Assoc 1995;87:746-8.
3. Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev 1996;17:302-32.
4. Mundy GR, Bertolini DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986;3:291-9.
5. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:529-530.
6. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992;49:192-98.
7. Klein B, Lu ZY, Gaillard JP, Harousseau JL, Bataille R. Inhibiting IL-6 in human multiple myeloma. Curr Top Microbiol Immunol 1992;182:237-344.
8. Epstein J. Myeloma phenotype: clues to disease origin and manifestation. Barlogie B, editor. Hematology/Oncology Clinics of North America. Philadelphia: WB Saunders, 1992;6:249-56.
9. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995;86:3123-31.
10. Al-Humidan A, Ralston SH, Hughes DE, Chapman K, Aarden L, Graham R, et al. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res 1991;6:3-8.
11. Linkhart TA, Linkhart SG, Strong DD. Interleukin-6 messenger RNA expression and interleukin-6 protein secretion in normal human osteoblast-like cells: regulation by interleukin-1. J Bone Miner Res 1991;6:1285-94.
12. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD. IL-6 stimulates osteoclast-like multinucleated cell formation in long-term human marrow cultures by inducing IL-1 release. J Immunol 1990;144:4226-30.
13. Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, et al. Interleukin-6: a potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992;89:46-52.
14. Ohsaki Y, Takahashi S, Scarcez T, Demulder A, Nishihara T, Williams R, et al. Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology 1992;131:2229-34.
15. Reddy SV, Takahashi S, Dallas M, Williams RE, Neckers L, Roodman GD. IL-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res 1994;9:753 -7.
16. Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Barlogie B, editor. Hematology/Oncology Clinics of North America. Philadelphia: WB Saunders, 1992;6:285-95.
17. Boyce BF, Yates AJP, Mundy GR. Bolus injections of recombinant human interleukin-1 cause transient hypocalcemia in normal mice. Endocrinology 1989;125:2780-83.
18. Garrett IR, Durie BGM, Nedwin GE, Gillespie A, Bringman T, Sabatini M, et al. Production of the bone resorbing cytokine lymphotoxin by cultured human myeloma cells. N Engl J Med 1987;317:526-32.
19. MacDonald BR, Mundy GR, Clark S, Wang EA, Kuehl TJ, Stanley ER, et al. Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. J Bone Miner Res 1986;1:227-33.
20. Barille S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995;86:3151-59.
21. Huang N, Kawano MM, Mahmoud MS, Mihara K, Tsujimoto T, Niwa O, et al. Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells. Blood 1995;85:3704-12.
22. Tatsumi T, Shimazaki C, Goto H, Araki S, Sudo Y, Yamagata N, et al. Expression of adhesion molecules on myeloma cells. Jpn J Cancer Res 1996;87:837-42.
23. Chauhan D, Uchiyama H, Urashima M, Yamamoto K, Anderson KC. Regulation of interleukin-6 in multiple myeloma and bone marrow stromal cells. Stem Cells 1995;13(suppl 2):35-9.
24. Van Riet I, Van Camp B. The involvement of adhesion molecules in the biology of multiple myeloma [review]. Leuk Lymph 1993;9:441-52.
25. Lokhorst HM, Lamme T, de Smet M, Klein S, de Weger RA, van Oers R, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994;84:2269-77.
26. Huang YW, Richardson JA, Tong AW, Zhang BQ, Stone MJ, Vitetta ES. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 1993;53:1392-6.
27. Tong AW, Huang YW, Zhang BQ, Netto G, Vitetta ES, Stone MJ. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. Anticancer Res 1993;13:593-7.
28. Alsina M, Boyce BF, Devlin R, Anderson JL, Craig F, Mundy GR, et al. Development of an in vivo model of human multiple myeloma bone disease. Blood 1996;87:1495-1501.
29. Hjorth-Hansen H, Borset M, Seidel C, Harseth H, Nordby A, Sundan A, et al. The JJN-3 cell line gives multiple myeloma with bone disease in SCID mice. Blood 1996;88:387abstract.
30. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992;49:192-8.
31. Wano Y, Hattori T, Matsuoka M, Takatsuki K, Chua AO, Gubler U, et al. Interleukin-1 gene expression in adult T cell leukemia. J Clin Invest 1987;80:911-6.
32. Mori N, Prager D. Transactivation of the interleukin-1 alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood 1996;87:3410-17.
33. Fetchick DA, Bertolini DR, Sarin PS, Weintraub ST, Mundy GR, Dunn JF. Production of 1,25-dihydroxyvitamin D3 by human T cell lymphotrophic virus-I-transformed lymphocytes. J Clin Invest 1986;78:592-6.
34. Johnston SR, Hammond PJ. Elevated serum parathyroid hormone related protein and 1,25-dihydroxycholecalciferol in hypercalcaemia associated with adult T-cell leukaemia-lymphoma. Postgrad Med J 1992;68:753-5.
35. Martin TJ, Grill V. Hypercalcemia in cancer [review]. J Steroid Biochem Mol Biol 1992;43:123-9.
36. Motokura T, Fukumoto S, Matsumoto T, Takahashi S, Fujita A, Yamashita T, et al. Parathyroid hormone-related protein in adult T-cell leukemia-lymphoma. Ann Intern Med 1989;111:484-8.
37. Seymour JR, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1993;82:1383-94.
38. Golconda MS, Larson TS, Kolb LG, Kumar R. 1,25-dihydroxyvitamin D-mediated hypercalcemia in a renal transplant recipient [review]. Mayo Clin Proc 1996;71:32-6.
39. Hicks DG, Gokan T, O'Keefe RJ, Totterman SM, Fultz PJ, Judkins AR, et al. Primary lymphoma of bone: correlation of magnetic resonance imaging features with cytokine production by tumor cells. Cancer 1995;75:973-80.